Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Gilead Sciences, the Morehouse School of Medicine and Xavier University boost HIV care for Black Americans in a COVID-impacted South.
Gilead Sciences’ “Zeroing In” program helps 116 grantees boost HIV innovation, education and outreach in marginalized communities.
The antiviral drug is the first treatment for the new coronavirus to be approved in United States.
Nine key findings from a survey of HIV-positive people 50 and older. Plus: A special report on aging with HIV during COVID-19.
FDA grants emergency use authorization, but randomized clinical trials of the antiviral drug show mixed results.
As a result, researchers in Spain are testing whether HIV med Truvada, often used as PrEP, can also prevent COVID-19.
The assurance arrives as the pharma giant cuts off most emergency access to remdesivir, a potential COVID-19 treatment.
Gilead Sciences is giving its antiviral remdesivir to nearly 1,000 people as part of two clinical trials.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.